KRAS and pancreatic ductal adenocarcinoma: KRAS wild-type pancreatic ductal adenocarcinoma accounts for approximately 10.7% to 12% of all PDAC cases, as reported by Philip et al. (2022) and Dorman et al. (2023) [35,36].